Table 5.
Total | Male | Female | |||||||
---|---|---|---|---|---|---|---|---|---|
β | 95%-CI | p-value | β | 95%-CI | p-value | β | 95%-CI | p-value | |
FEV1a | |||||||||
SHS exposureb | −44 | (−82, −5) | 0.03 | −75 | (− 140, − 11) | 0.02 | −13 | (− 57, 31) | 0.56 |
SHS exposure*follow-up timec | 1 | (0, 3) | 0.03 | 2 | (0, 4) | 0.03 | 1 | (−1, 3) | 0.19 |
FVCa | |||||||||
SHS exposureb | − 56 | (−102, − 10) | 0.02 | − 102 | (− 179, − 24) | 0.01 | −19 | (−71, 33) | 0.47 |
SHS exposure*follow-up timec | 2 | (0, 4) | 0.02 | 3 | (0, 6) | 0.03 | 2 | (0, 4) | 0.09 |
FEV1/FVCa | |||||||||
SHS exposureb | 0.0 | (− 0.5, 0.5) | 0.96 | 0.1 | (− 0.6, 0.9) | 0.71 | 0.1 | (−0.6, 0.7) | 0.88 |
SHS exposure*follow-up timec | 0.0 | (0.0, 0.0) | 0.94 | 0.0 | (0.0, 0.0) | 0.96 | 0.0 | (0.0, 0.0) | 0.62 |
Models are adjusted for age, age squared, weight, weight squared, height, combination of smoking status and pack years, maternal smoking, paternal smoking, allergic sensitisation, education and exposure to dust/fumes as well as for sex in the total study population
aan interaction term between time between follow-ups and SHS exposure is included to determine the effect of SHS exposure on lung function decline
ba negative estimate suggests that those exposed to SHS at the first examination had lower average lung function at all three examinations than those not exposed
ca negative estimate suggests that those exposed to SHS at the first examination had a higher decline in lung function between the examinations than those not exposed
* indicating the interaction term between SHS exposure and time of follow-up